Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

January 14, 2026 updated by: Petrovsky National Research Centre of Surgery

Determination the Safety of Disaggregant and Anticoagulant Therapy in the Development of Complications in Noncardiac Vascular Surgery.

The goal of this retrospective clinical trial is to find out association antiplatelet and anticoagulant therapy with perioperative complications in non-cardiac vascular surgery in patients . The main questions it aims to answer are:

Does the use of antiplatelet agents and anticoagulants affect the development of complications in the perioperative period during operations on the main arteries? Does discontinuing antiplatelet and anticoagulant medications affect the development of perioperative complications in major artery surgeries?? Researchers will compare with patients who didn't use antiplatelets and anticoagulant drugs to see ift he incidence of complications comparable?

This is a retrospective study based on the analysis of medical records (case histories).

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Russia
      • Moscow, Russia, 119991
        • NRCS Petrovsky

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with surgical treatment of atherosclerotic lesions of the main arteries.

Description

Inclusion Criteria:

  • Patients who received surgical treatment on the main arteries.

Exclusion Criteria:

  • Patients who received surgical treatment on the main veins.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control
Patients who did not take antiplatelet agents and anticoagulants
Antiplatelet and anticoagulants
Patients who use antiplatelet agents and anticoagulants until the operation day
Drug: Aspirin
Patients who take aspirin until the operation day
Drug: Clopidogrel
Patients who take clopidogrel until the operation day
Drug: Ticagrelor
Patients who take ticagrelor until the operation day
Drug: Dabigatran
Patients who take dabigatran until the operation day
Drug: Rivaroxaban
Patients who take rivaroxaban until the operation day
Drug: Apixaban
Patients who take apixaban until the operation day
Drug: Warfarin
Patients who take warfarin until the operation day
Drug: aspirin + clopidogrel
Patients who take aspirin and clopidogrel until the operation day
Drug: Aspirin + Ticagrelor
Patients who take aspirin and ticagrelor until the operation day
Drug: Aspirin + Apixaban
Patients who take aspirin and apixaban until the operation day
Drug: Aspirin + rivaroxaban
Patients who take aspirin and rivaroxaban until the operation day
Drug: Clopidogrel + Apixaban
Patients who take clopidogrel and apixaban until the operation day
Drug: Clopidogrel + Rivaroxaban
Patients who take clopidogrel and rivaroxaban until the operation day
Discontinuation of antiplatelet and anticoagulants
Patients who discontinuate antiplatelet agents and anticoagulants until the operation day

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bleeding
Time Frame: First 24 hours after operation
Case of bleeding or haematoma development
First 24 hours after operation

Secondary Outcome Measures

Outcome Measure
Time Frame
Trombosis
Time Frame: First 24 hours after operation
First 24 hours after operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Petrovsky National Research Centre of Surgery

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2025

Primary Completion (Estimated)

February 12, 2026

Study Completion (Estimated)

February 28, 2026

Study Registration Dates

First Submitted

January 14, 2026

First Submitted That Met QC Criteria

January 14, 2026

First Posted (Actual)

January 22, 2026

Study Record Updates

Last Update Posted (Actual)

January 22, 2026

Last Update Submitted That Met QC Criteria

January 14, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ComplVasc2025Retro

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thrombosis

Clinical Trials on Aspirin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe